Navigating the Biosimilar Landscape: What to watch out in 2024 and Beyond
The anticipated expiration of exclusivity rights for major biologics in 2022…
Biosimilars: Enhancing physician uptake in the EU
At the moment, EU physicians seem much more comfortable than their US…
The curious case of biosimilar launches in the US
The Biologics Price Competition and Innovation Act (BPCI Act) of 2009 provided…